SVEP1
Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1
Also known as: bA427L11.3, C9orf13, FLJ13529, POLYDOM, SVEP1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q4LDE5
- Gene
- SVEP1
- Ensembl
- ENSG00000165124
- Chromosome
- 9
- Canonical length
- 3571 aa
- Protein class
- Predicted intracellular proteins
- Secretome location
- Intracellular and membrane
OverviewNCBI Gene
Enables integrin binding activity. Involved in negative regulation of vasoconstriction and positive regulation of platelet activation. Located in cytoplasm and nucleus. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
3571 residues, UniProt reviewed canonical sequence.
>Q4LDE5|SVEP1
1 MWPRLAFCCW GLALVSGWAT FQQMSPSRNF SFRLFPETAP GAPGSIPAPP APGDEAAGSR
61 VERLGQAFRR RVRLLRELSE RLELVFLVDD SSSVGEVNFR SELMFVRKLL SDFPVVPTAT
121 RVAIVTFSSK NYVVPRVDYI STRRARQHKC ALLLQEIPAI SYRGGGTYTK GAFQQAAQIL
181 LHARENSTKV VFLITDGYSN GGDPRPIAAS LRDSGVEIFT FGIWQGNIRE LNDMASTPKE
241 EHCYLLHSFE EFEALARRAL HEDLPSGSFI QDDMVHCSYL CDEGKDCCDR MGSCKCGTHT
301 GHFECICEKG YYGKGLQYEC TACPSGTYKP EGSPGGISSC IPCPDENHTS PPGSTSPEDC
361 VCREGYRASG QTCELVHCPA LKPPENGYFI QNTCNNHFNA ACGVRCHPGF DLVGSSIILC
421 LPNGLWSGSE SYCRVRTCPH LRQPKHGHIS CSTREMLYKT TCLVACDEGY RLEGSDKLTC
481 QGNSQWDGPE PRCVERHCST FQMPKDVIIS PHNCGKQPAK FGTICYVSCR QGFILSGVKE
541 MLRCTTSGKW NVGVQAAVCK DVEAPQINCP KDIEAKTLEQ QDSANVTWQI PTAKDNSGEK
601 VSVHVHPAFT PPYLFPIGDV AIVYTATDLS GNQASCIFHI KVIDAEPPVI DWCRSPPPVQ
661 VSEKVHAASW DEPQFSDNSG AELVITRSHT QGDLFPQGET IVQYTATDPS GNNRTCDIHI
721 VIKGSPCEIP FTPVNGDFIC TPDNTGVNCT LTCLEGYDFT EGSTDKYYCA YEDGVWKPTY
781 TTEWPDCAKK RFANHGFKSF EMFYKAARCD DTDLMKKFSE AFETTLGKMV PSFCSDAEDI
841 DCRLEENLTK KYCLEYNYDY ENGFAIGPGG WGAANRLDYS YDDFLDTVQE TATSIGNAKS
901 SRIKRSAPLS DYKIKLIFNI TASVPLPDER NDTLEWENQQ RLLQTLETIT NKLKRTLNKD
961 PMYSFQLASE ILIADSNSLE TKKASPFCRP GSVLRGRMCV NCPLGTYYNL EHFTCESCRI
1021 GSYQDEEGQL ECKLCPSGMY TEYIHSRNIS DCKAQCKQGT YSYSGLETCE SCPLGTYQPK
1081 FGSRSCLSCP ENTSTVKRGA VNISACGVPC PEGKFSRSGL MPCHPCPRDY YQPNAGKAFC
1141 LACPFYGTTP FAGSRSITEC SSFSSTFSAA EESVVPPASL GHIKKRHEIS SQVFHECFFN
1201 PCHNSGTCQQ LGRGYVCLCP LGYTGLKCET DIDECSPLPC LNNGVCKDLV GEFICECPSG
1261 YTGQRCEENI NECSSSPCLN KGICVDGVAG YRCTCVKGFV GLHCETEVNE CQSNPCLNNA
1321 VCEDQVGGFL CKCPPGFLGT RCGKNVDECL SQPCKNGATC KDGANSFRCL CAAGFTGSHC
1381 ELNINECQSN PCRNQATCVD ELNSYSCKCQ PGFSGKRCET EQSTGFNLDF EVSGIYGYVM
1441 LDGMLPSLHA LTCTFWMKSS DDMNYGTPIS YAVDNGSDNT LLLTDYNGWV LYVNGREKIT
1501 NCPSVNDGRW HHIAITWTSA NGIWKVYIDG KLSDGGAGLS VGLPIPGGGA LVLGQEQDKK
1561 GEGFSPAESF VGSISQLNLW DYVLSPQQVK SLATSCPEEL SKGNVLAWPD FLSGIVGKVK
1621 IDSKSIFCSD CPRLGGSVPH LRTASEDLKP GSKVNLFCDP GFQLVGNPVQ YCLNQGQWTQ
1681 PLPHCERISC GVPPPLENGF HSADDFYAGS TVTYQCNNGY YLLGDSRMFC TDNGSWNGVS
1741 PSCLDVDECA VGSDCSEHAS CLNVDGSYIC SCVPPYTGDG KNCAEPIKCK APGNPENGHS
1801 SGEIYTVGAE VTFSCQEGYQ LMGVTKITCL ESGEWNHLIP YCKAVSCGKP AIPENGCIEE
1861 LAFTFGSKVT YRCNKGYTLA GDKESSCLAN SSWSHSPPVC EPVKCSSPEN INNGKYILSG
1921 LTYLSTASYS CDTGYSLQGP SIIECTASGI WDRAPPACHL VFCGEPPAIK DAVITGNNFT
1981 FRNTVTYTCK EGYTLAGLDT IECLADGKWS RSDQQCLAVS CDEPPIVDHA SPETAHRLFG
2041 DIAFYYCSDG YSLADNSQLL CNAQGKWVPP EGQDMPRCIA HFCEKPPSVS YSILESVSKA
2101 KFAAGSVVSF KCMEGFVLNT SAKIECMRGG QWNPSPMSIQ CIPVRCGEPP SIMNGYASGS
2161 NYSFGAMVAY SCNKGFYIKG EKKSTCEATG QWSSPIPTCH PVSCGEPPKV ENGFLEHTTG
2221 RIFESEVRYQ CNPGYKSVGS PVFVCQANRH WHSESPLMCV PLDCGKPPPI QNGFMKGENF
2281 EVGSKVQFFC NEGYELVGDS SWTCQKSGKW NKKSNPKCMP AKCPEPPLLE NQLVLKELTT
2341 EVGVVTFSCK EGHVLQGPSV LKCLPSQQWN DSFPVCKIVL CTPPPLISFG VPIPSSALHF
2401 GSTVKYSCVG GFFLRGNSTT LCQPDGTWSS PLPECVPVEC PQPEEIPNGI IDVQGLAYLS
2461 TALYTCKPGF ELVGNTTTLC GENGHWLGGK PTCKAIECLK PKEILNGKFS YTDLHYGQTV
2521 TYSCNRGFRL EGPSALTCLE TGDWDVDAPS CNAIHCDSPQ PIENGFVEGA DYSYGAIIIY
2581 SCFPGFQVAG HAMQTCEESG WSSSIPTCMP IDCGLPPHID FGDCTKLKDD QGYFEQEDDM
2641 MEVPYVTPHP PYHLGAVAKT WENTKESPAT HSSNFLYGTM VSYTCNPGYE LLGNPVLICQ
2701 EDGTWNGSAP SCISIECDLP TAPENGFLRF TETSMGSAVQ YSCKPGHILA GSDLRLCLEN
2761 RKWSGASPRC EAISCKKPNP VMNGSIKGSN YTYLSTLYYE CDPGYVLNGT ERRTCQDDKN
2821 WDEDEPICIP VDCSSPPVSA NGQVRGDEYT FQKEIEYTCN EGFLLEGARS RVCLANGSWS
2881 GATPDCVPVR CATPPQLANG VTEGLDYGFM KEVTFHCHEG YILHGAPKLT CQSDGNWDAE
2941 IPLCKPVNCG PPEDLAHGFP NGFSFIHGGH IQYQCFPGYK LHGNSSRRCL SNGSWSGSSP
3001 SCLPCRCSTP VIEYGTVNGT DFDCGKAARI QCFKGFKLLG LSEITCEADG QWSSGFPHCE
3061 HTSCGSLPMI PNAFISETSS WKENVITYSC RSGYVIQGSS DLICTEKGVW SQPYPVCEPL
3121 SCGSPPSVAN AVATGEAHTY ESEVKLRCLE GYTMDTDTDT FTCQKDGRWF PERISCSPKK
3181 CPLPENITHI LVHGDDFSVN RQVSVSCAEG YTFEGVNISV CQLDGTWEPP FSDESCSPVS
3241 CGKPESPEHG FVVGSKYTFE STIIYQCEPG YELEGNRERV CQENRQWSGG VAICKETRCE
3301 TPLEFLNGKA DIENRTTGPN VVYSCNRGYS LEGPSEAHCT ENGTWSHPVP LCKPNPCPVP
3361 FVIPENALLS EKEFYVDQNV SIKCREGFLL QGHGIITCNP DETWTQTSAK CEKISCGPPA
3421 HVENAIARGV HYQYGDMITY SCYSGYMLEG FLRSVCLENG TWTSPPICRA VCRFPCQNGG
3481 ICQRPNACSC PEGWMGRLCE EPICILPCLN GGRCVAPYQC DCPPGWTGSR CHTAVCQSPC
3541 LNGGKCVRPN RCHCLSSWTG HNCSRKRRTG FLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SVEP1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0
- Highest tissue expression
- 58 nTPM
Expression across tissuesHPA
Tissue
- placenta: 58 nTPM
- adipose tissue: 37 nTPM
- breast: 23 nTPM
- lung: 19 nTPM
- blood vessel: 12 nTPM
- vagina: 12 nTPM
Single-cell type
- fibro-adipogenic progenitors: 857 nCPM
- adipocytes: 723 nCPM
- syncytiotrophoblasts: 610 nCPM
- mesothelial cells: 470 nCPM
- fibroblasts: 350 nCPM
- epicardial cells: 214 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebellum: 24 nTPM
- basal ganglia: 24 nTPM
- white matter: 18 nTPM
- midbrain: 16 nTPM
- thalamus: 14 nTPM
- cerebral cortex: 13 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.25
- gnomAD pLI
- 1
- gnomAD missense Z
- 1.88
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- epidermis development
- gene expression
- lymph circulation
- lymph vessel morphogenesis
- negative regulation of vasoconstriction
- positive regulation of platelet activation
- Tie signaling pathway
- tight junction organization
Molecular functions
- calcium ion binding
- chromatin binding
- integrin binding
- integrin binding involved in cell-matrix adhesion
Cellular components
Protein domainsUniProt · Pfam · InterPro
- EGF-type aspartate/asparagine hydroxylation site
- Sushi/SCR/CCP domain
- EGF-like domain
- Pentraxin domain
- EGF-like calcium-binding domain
- von Willebrand factor, type A
- HYR domain
- Growth factor receptor cysteine-rich domain superfamily
- Tyrosine-protein kinase ephrin type A/B receptor-like
- EGF-like, conserved site
- Concanavalin A-like lectin/glucanase domain superfamily
- EGF-like calcium-binding, conserved site
- Sushi/SCR/CCP superfamily
- von Willebrand factor A-like domain superfamily
- NOTCH1, EGF-like calcium-binding domain
- Complement & Cell Adhesion Regulators
- EGF-like domain
- Sushi repeat (SCR repeat)
- von Willebrand factor type A domain
- Pentaxin family
- HYR domain
- Calcium-binding EGF domain
- Tyrosine-protein kinase ephrin type A/B receptor-like
- Human growth factor-like EGF
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SVEP1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SVEP1 as an antibody target. Whether an autoantibody or antibody against SVEP1 could matter depends on whether native SVEP1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SVEP1 is annotated as secreted, so native SVEP1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label SVEP1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...